Marshall Wace, LLP Abb Vie Inc. Call Options Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $25.9 Million - $29.2 Million	188,300 New	188,300 $29.2 Million
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $8.81 Million - $11 Million	66,500 Added 1072.58%	72,700 $9.79 Million
Q1 2023 May 15, 2023	BUY	$144.61 - $166.54 $896,582 - $1.03 Million	6,200 New	6,200 $988,000
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $1.02 Million - $1.17 Million	7,600 New	7,600 $1.02 Million
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $1.66 Million - $1.88 Million	-15,600 Reduced 98.11%	300 $32,000

Q1 2021 May 17, 2021	BUY	$102.3 - $112.62 $1.63 Million - $1.79 Million	15,900 New	15,900 $1.72 Million

3,651

1.24B

15.5M

11.6M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $303B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.